Table I.
Epidemiology and duration of early-stage (ES) mycosis fungoides (MF)
| UK | US | US SEERa early-stage | |
|---|---|---|---|
| Cohort period | 2013b | 2001–2005c | 2005–2015 |
| Age at diagnosis | |||
| Median | 54d | mean: 55.3e | 59 |
| ≥ 63 years old, % | 35.0 | Not reported | 41.8 |
| Male, % | 61.5d | 52.4e | 57.8 |
| Epidemiology | |||
| Incidence MF/100,000 py | 0.37b | 0.41c | 0.53 |
| Proportion at ES, % | 71d | 71.5e | f- |
| Incidence ES-MF/100,000 py | 0.26 | 0.29 | 0.38 |
| Prevalence ES-MF/100,000 | 4.8 | 5.2 | 6.6 |
| Prognosis | |||
| Survival | |||
| Median overall survival, years | 27.1d | – | 23.9 |
| 5-year overall survival, % | 87.9d | 92e | 86.1 |
| Risk of disease progression, % | – | ||
| 5-years | 15.5d | 16e | – |
| 1-year (estimated) | 3.2d | 3.4e | – |
| Time to progression | |||
| Median progression: patients diagnosed <63 years old | 21.7 | 20.4 | – |
| Median duration of early-stage disease: adjusting for life-expectancy | 18.4 | 17.6 | – |
a
Results from Surveillance, Epidemiology, and End Results (SEER) cancer registry analyses on 3,132 patients with early-stage mycosis fungoides
b
UK Public Health England
c
Bradford et al. (18)
d
Agar et al. (1)
e
Talpur et al. (19)
f
% ES-MF not reported due to missing Tumour-Node-Metastasis data – Talpur et al. estimate used; py: person-years.